BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019;380:1001-11. [PMID: 30865794 DOI: 10.1056/NEJMoa1806808] [Cited by in Crossref: 110] [Cited by in F6Publishing: 49] [Article Influence: 55.0] [Reference Citation Analysis]
Number Citing Articles
1 Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, Sean Cavanaugh J. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther 2020;17:40. [PMID: 32650797 DOI: 10.1186/s12981-020-00296-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS 2021;32:780-90. [PMID: 33612015 DOI: 10.1177/0956462421992257] [Reference Citation Analysis]
3 Buck WC, Nguyen H, Siapka M, Basu L, Greenberg Cowan J, De Deus MI, Gleason M, Ferreira F, Xavier C, Jose B, Muthemba C, Simione B, Kerndt P. Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment. AIDS Res Ther 2021;18:3. [PMID: 33422091 DOI: 10.1186/s12981-020-00325-9] [Reference Citation Analysis]
4 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Harries AD, Kumar AMV, Satyanarayana S, Thekkur P, Lin Y, Dlodlo RA, Khogali M, Zachariah R. The Growing Importance of Tuberculosis Preventive Therapy and How Research and Innovation Can Enhance Its Implementation on the Ground. Trop Med Infect Dis 2020;5:E61. [PMID: 32316300 DOI: 10.3390/tropicalmed5020061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Hatherill M, Chaisson RE, Denkinger CM. Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies. PLoS Med 2019;16:e1002795. [PMID: 31039150 DOI: 10.1371/journal.pmed.1002795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Nathavitharana RR, van der Westhuizen A, van der Westhuizen HM, Mishra H, Sampson A, Meintjes J, Nardell E, McDowell A, Theron G. "If I've got latent TB, I would like to get rid of it": Derivation of the CARD (Constraints, Actions, Risks, and Desires) Framework informed by South African healthcare worker perspectives on latent tuberculosis treatment. PLoS One 2021;16:e0254211. [PMID: 34407070 DOI: 10.1371/journal.pone.0254211] [Reference Citation Analysis]
9 Wong K, Nguyen J, Blair L, Banjanin M, Grewal B, Bowman S, Boyd H, Gerstner G, Cho HJ, Panfilov D, Tam CK, Aguilar D, Venketaraman V. Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection. J Clin Med 2020;9:E3575. [PMID: 33172001 DOI: 10.3390/jcm9113575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Eisinger RW, Embry AC, Read SW, Fauci AS. 2019: A Banner Year for Tuberculosis Research. J Infect Dis 2020;222:1768-71. [PMID: 32043109 DOI: 10.1093/infdis/jiaa051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Mecha J, Escudero JN, Hawn TR, John-Stewart G. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. Clin Infect Dis 2021;73:e337-44. [PMID: 32564076 DOI: 10.1093/cid/ciaa827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jeon D. Latent tuberculosis infection: recent progress and challenges in South Korea. Korean J Intern Med 2020;35:269-75. [PMID: 32131570 DOI: 10.3904/kjim.2020.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
13 Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence. J Int AIDS Soc 2020;23:e25481. [PMID: 32202066 DOI: 10.1002/jia2.25481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Villa S, Ferrarese M, Sotgiu G, Castellotti PF, Saderi L, Grecchi C, Saporiti M, Raviglione M, Codecasa LR. Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. J Clin Med 2019;9:E101. [PMID: 31906078 DOI: 10.3390/jcm9010101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kim PS, Swaminathan S. Ending TB: the world's oldest pandemic. J Int AIDS Soc 2021;24:e25698. [PMID: 33754449 DOI: 10.1002/jia2.25698] [Reference Citation Analysis]
16 Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, Muñoz L, Gosce L, Rangaka MX, Francis M, Hack V, Kunst H, Abubakar I. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study. BMC Infect Dis 2021;21:90. [PMID: 33478428 DOI: 10.1186/s12879-021-05766-9] [Reference Citation Analysis]
17 Ferguson O, Jo Y, Pennington J, Johnson K, Chaisson RE, Churchyard G, Dowdy D. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2020;23:e25623. [PMID: 33073520 DOI: 10.1002/jia2.25623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Glob Public Health 2021;:1-14. [PMID: 33650939 DOI: 10.1080/17441692.2021.1892793] [Reference Citation Analysis]
19 Lalvani A, Berrocal-Almanza LC, Halliday A. Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination. PLoS Med 2019;16:e1002814. [PMID: 31125334 DOI: 10.1371/journal.pmed.1002814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
20 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69:1-11. [PMID: 32053584 DOI: 10.15585/mmwr.rr6901a1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 54.0] [Reference Citation Analysis]
21 Podany AT, Leon-Cruz J, Hakim J, Supparatpinyo K, Omoz-Oarhe A, Langat D, Mwelase N, Kanyama C, Gupta A, Benson CA, Chaisson RE, Swindells S, Fletcher CV; AIDS Clinical Trials Group A5279 Team. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother 2021;76:718-21. [PMID: 33241266 DOI: 10.1093/jac/dkaa470] [Reference Citation Analysis]
22 Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nat Commun 2021;12:424. [PMID: 33462224 DOI: 10.1038/s41467-020-20731-x] [Reference Citation Analysis]
23 Kasibante J, Rutakingirwa MK, Kagimu E, Ssebambulidde K, Ellis J, Tugume L, Mpoza E, Cresswell F, Meya DB. Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician's perspective. J Clin Tuberc Other Mycobact Dis 2020;20:100180. [PMID: 32875123 DOI: 10.1016/j.jctube.2020.100180] [Reference Citation Analysis]
24 Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med 2019;16:e1002882. [PMID: 31415563 DOI: 10.1371/journal.pmed.1002882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
25 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Mandal S, Bhatia V, Sharma M, Mandal PP, Arinaminpathy N. The potential impact of preventive therapy against tuberculosis in the WHO South-East Asian Region: a modelling approach. BMC Med 2020;18:163. [PMID: 32684164 DOI: 10.1186/s12916-020-01651-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Agizew T, Surie D, Oeltmann JE, Letebele M, Pals S, Mathebula U, Mathoma A, Kassa M, Hamda S, Pono P, Rankgoane-Pono G, Boyd R, Auld A, Finlay A. Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits. Public Health Action 2020;10:64-9. [PMID: 32639479 DOI: 10.5588/pha.19.0056] [Reference Citation Analysis]
28 Churchyard GJ, Swindells S. Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. PLoS Med 2019;16:e1002787. [PMID: 31013273 DOI: 10.1371/journal.pmed.1002787] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
29 Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci 2020;15:65. [PMID: 32787925 DOI: 10.1186/s13012-020-01025-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G, Oxlade O, Menzies D. Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLoS Med 2021;18:e1003738. [PMID: 34520459 DOI: 10.1371/journal.pmed.1003738] [Reference Citation Analysis]
31 Lee MR, Huang HL, Lin SW, Cheng MH, Lin YT, Chang SY, Yan BS, Kuo CH, Lu PL, Wang JY, Chong IW. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. J Clin Med 2019;8:E812. [PMID: 31174321 DOI: 10.3390/jcm8060812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Miyahara S, Ramchandani R, Kim S, Evans SR, Gupta A, Swindells S, Chaisson RE, Montepiedra G. Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials. Clin Infect Dis 2020;70:698-703. [PMID: 31414121 DOI: 10.1093/cid/ciz784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
34 Dyavar SR, Mykris TM, Winchester LC, Scarsi KK, Fletcher CV, Podany AT. Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics. Sci Rep 2020;10:12565. [PMID: 32724080 DOI: 10.1038/s41598-020-69228-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
35 Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Am J Respir Crit Care Med 2020;202:866-77. [PMID: 32412342 DOI: 10.1164/rccm.201912-2489OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
36 Sullivan K, Pease C, Zwerling A, Mallick R, Van Dyk D, Mulpuru S, Allen C, Alsdurf H, Alvarez GG. Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country. BMC Public Health 2021;21:964. [PMID: 34020616 DOI: 10.1186/s12889-021-10733-9] [Reference Citation Analysis]
37 Click ES, Kurbatova EV, Alexander H, Dalton TL, Chen MP, Posey JE, Ershova J, Cegielski JP. Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion. J Infect Dis 2020;221:2072-82. [PMID: 32002554 DOI: 10.1093/infdis/jiaa042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
38 Mandalakas AM, Hesseling AC, Kay A, Du Preez K, Martinez L, Ronge L, DiNardo A, Lange C, Kirchner HL. Tuberculosis prevention in children: a prospective community-based study in South Africa. Eur Respir J 2021;57:2003028. [PMID: 33122339 DOI: 10.1183/13993003.03028-2020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents 2021;57:106220. [PMID: 33166693 DOI: 10.1016/j.ijantimicag.2020.106220] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
40 Montepiedra G, Ramchandani R, Miyahara S, Kim S. A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches. Stat Med 2021;40:327-48. [PMID: 33105524 DOI: 10.1002/sim.8777] [Reference Citation Analysis]
41 Hatherill M, White RG, Hawn TR. Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Front Microbiol 2019;10:3154. [PMID: 32082273 DOI: 10.3389/fmicb.2019.03154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
42 Ilaiwy G, Dowdy DW. Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees. J Clin Tuberc Other Mycobact Dis 2021;24:100262. [PMID: 34368467 DOI: 10.1016/j.jctube.2021.100262] [Reference Citation Analysis]
43 Sterling TR, Lin PL. Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. J Clin Invest 2020;130:5102-4. [PMID: 32831291 DOI: 10.1172/JCI137294] [Reference Citation Analysis]
44 Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A;  IMPAACT P1078 TB APPRISE Study Team. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. N Engl J Med. 2019;381:1333-1346. [PMID: 31577875 DOI: 10.1056/nejmoa1813060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
45 Esmail H, Cobelens F, Goletti D. Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. Eur Respir J 2020;55:1901957. [PMID: 31949119 DOI: 10.1183/13993003.01957-2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
46 Boyd AT, Lodiongo DK, Benson JM, Aragaw S, Pasquale MS, Ayalneh H, Olemukan R, Avaku I, Baabe N, Achut V, Chun H, Bunga S. Implementation of tuberculosis preventive treatment among people living with HIV, South Sudan. Bull World Health Organ 2021;99:34-40. [PMID: 33716332 DOI: 10.2471/BLT.20.254789] [Reference Citation Analysis]
47 Makita-Chingombe F, Podany AT, Mykris T, Muzambi F, Browne RW, Ocque AJ, DiFrancesco R, Winchester LC, Fletcher CV, Mudzviti T, Maponga CC, Morse GD. Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in Zimbabwe. Afr J Lab Med 2021;10:1264. [PMID: 34395199 DOI: 10.4102/ajlm.v10i1.1264] [Reference Citation Analysis]
48 Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer 2021;9:e001664. [PMID: 33782108 DOI: 10.1136/jitc-2020-001664] [Reference Citation Analysis]
49 Mehtani NJ, Puryear S, Pham P, Dooley KE, Shah M. Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab319. [PMID: 34395707 DOI: 10.1093/ofid/ofab319] [Reference Citation Analysis]